Recent Updates — ENTX

Entera Bio Ltd. appointed Dr. Juan Camilo Arjona Ferreira, currently Head of R&D and CMO at Organon & Co., to its Board of Directors effective December 1, 2026. He will serve as a Class II director until the 2027 Annual Meeting and join the compensation committee. Dr. Arjona Ferreira succeeds Haya Taitel, who is stepping down from the board. The company operates in the biotechnology sector, developing oral peptide therapies for conditions such as osteoporosis.

Entera Bio appointed Laura Hamill as a Class I director effective December 1, 2026. Hamill brings over 35 years of commercial leadership experience from Gilead Sciences and Amgen. She joins the audit and corporate governance committees. Yonatan Malca is stepping down from the Board on the same date to succeed him. Entera develops oral peptide therapies for conditions including osteoporosis.

Entera Bio Ltd. entered into a Securities Purchase Agreement on July 26, 2026, closing on July 28, 2026, to raise approximately $275.0 million in a private placement. The company issued 122,961,215 ordinary shares and 11,842,695 pre-funded warrants at a price of $2.04 per share. Proceeds will fund the Phase 3 registrational study of EB613 for postmenopausal osteoporosis and general working capital. BVF Partners L.P. received the right to designate two board directors, contingent on maintaining specific ownership thresholds. The company agreed to appoint two new independent directors by the 2027 annual meeting, triggering the resignation of current directors Haya Taitel and Yonatan Malca. Entera Bio Ltd. operates in the biotechnology industry, developing therapies for metabolic and bone diseases.